Disclosure Of First-Time Adoption [Text Block]

Xspray Pharma - Filing #690673

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	556 019 SEK	—	—	—	—	976,000 SEK	375 057 SEK	22 680 SEK	907 420 SEK	—	243 387 SEK	976,000 SEK	813 483 SEK	—	591 752 SEK	—	20 680 SEK	—	—	—	146 689 SEK	709 407 SEK	18 893 SEK	976,000 SEK	582 587 SEK
Comprehensive income	—	– SEK	– SEK	131 670 SEK	131 670 SEK	—	—	—	—	– SEK	—	—	—	– SEK	—	– SEK	—	– SEK	96 698 SEK	96 698 SEK	—	—	—	—	—
Profit (loss)	—	– SEK	– SEK	131 670 SEK	131 670 SEK	—	—	—	—	– SEK	—	—	—	– SEK	—	– SEK	—	– SEK	96 698 SEK	96 698 SEK	—	—	—	—	—